Glucocorticoids for treating paediatric pulmonary hypertension: A novel use for a common medication by Aggarwal, Manish & Grady, Ronald M




Glucocorticoids for treating paediatric pulmonary
hypertension: A novel use for a common
medication
Manish Aggarwal
Washington University School of Medicine in St. Louis
Ronald M. Grady
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Aggarwal, Manish and Grady, Ronald M., ,"Glucocorticoids for treating paediatric pulmonary hypertension: A novel use for a
common medication." Cardiology in the Young.,. 1-3. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5912
Brief Report
Glucocorticoids for treating paediatric pulmonary hypertension:
a novel use for a common medication
Manish Aggarwal, Ronald Mark Grady
Division of Pediatric Cardiology, Washington University in St. Louis, St. Louis, Missouri, United States of America
Abstract Laboratory investigations have shown the role of inﬂammation in the pathogenesis of pulmonary
hypertension and improvement after anti-inﬂammatory drugs. Despite these observations, reports on the use of steroids
to treat pulmonary hypertension in humans are absent from the literature. In this article, we report the use of
glucocorticoids in the treatment of two children with pulmonary hypertension, demonstrating its potential utility.
Keywords: Pulmonary hypertension; inﬂammation; glucocorticoids
Received: 28 November 2016; Accepted: 24 February 2017
PULMONARY HYPERTENSION IN CHILDREN IS Adevastating diagnosis with signiﬁcant morbidityand mortality. Causes for pulmonary hyperten-
sion in children include idiopathic pulmonary arter-
iolar dysfunction, CHD, and chronic lung disease,
especially in premature infants.1 Robust laboratory
investigations have shown that inﬂammation disrupts
multiple molecular pathways leading to pulmonary
hypertension. Inﬂammatory cell lines and elevated
pro-inﬂammatory cytokines have been identiﬁed
in tissue and sera from patients with pulmonary
hypertension.2 In rats, dexamethasone has been shown
to attenuate the development of pulmonary hyperten-
sion and even reverse the pathology.3,4 Human smooth
muscle cell growth is inhibited by prednisolone
in vitro.5 Despite the literature on anti-inﬂammatory
medications in treatment of pulmonary hypertension,
limited literature exists on treating pulmonary
hypertension with anti-inﬂammatory medications in
humans. In this article, we present the cases of two
children with severe pulmonary hypertension that
improved when treated with glucocorticoids.
Patient one was a former 31-week-gestation infant
with an uncomplicated intensive care course who
presented at 6 months of age to an outside hospital with
respiratory distress and hypoxia. Support was rapidly
escalated with intubation, muscle paralysis, and
multiple inotropes. All viral and bacterial cultures were
negative. An echocardiogram showed suprasystemic
right heart pressures (tricuspid regurgitation jet derived
pressure 106mmHg, systolic blood pressure 60mmHg,
and paradoxical ventricular septal motion with
“pancaked” left ventricle), and she was transferred for a
lung transplant evaluation. A cardiac catheterisation
performedwhilemechanically ventilated,muscle relaxed,
and on 100% oxygen, 20ppm of inhaled nitrous oxide,
oral sildenaﬁl, dopamine, and epinephrine demonstrated
suprasystemic right ventricular pressures (right
ventricular systolic pressure 103mmHg, left ventricular
systolic pressure 57mmHg, indexed pulmonary vascular
resistance of 25.7 Wood units×m2). Intravenous
epoprostenol was subsequently initiated. Over the next
3 days, the child’s clinical condition continued to dete-
riorate with worsening spells of hypoxia and hypotension.
Within 48 hours of initiating methylprednisolone at
2mg/kg/day, the child’s clinical course improved sig-
niﬁcantly with no further spells and a reduction in
inotropic support and oxygen. An open lung biopsy
found non-speciﬁc features of diffusemedial hypertrophy,
normal venules and capillaries, and rare lymphocytes.
After 11 days, she was weaned off steroids with
improved right ventricular function and septal position
though an insufﬁcient tricuspid regurgitation jet on
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echocardiograms. The child was transferred out of the
ICU on supplemental oxygen, increased dose of
epoprostenol, and sildenaﬁl. The child developed
worsening respiratory distress and hypoxia 10 days after
stopping steroids. Oral prednisone 2mg/kg/day was
again initiated and with notable clinical improvement
within 36 hours. The child was discharged home, and
steroids were successfully weaned over a 3-month period.
The child continues to thrive, and has been weaned off all
pulmonary vasodilators in the 9 years since treatment.
Patient two had Trisomy 21, and was initially seen
at 1 month of age with a moderate-sized, atrial-level
defect, no ventricular septal defect, and evidence of
suprasystemic right heart pressures with a pancaked
left ventricle. Cardiac catheterisation at 3 months
of age showed systemic right ventricular pressures
(mean pulmonary arterial pressure 44mmHg, indexed
pulmonary vascular resistance 4.7 Woods units×m2)
with minimal responsiveness to inhaled nitric oxide.
At 5 months of age, the atrial defect was surgically
closed without complications, and he was discharged
home on sildenaﬁl. Follow-up at 8 months of age,
however, showed pancaked interventricular septum
and suprasystemic pulmonary pressures (tricuspid
valve regurgitation jet derived pressure of 70mmHg),
and the child clinically had poor feeding and
diaphoresis. A 5-day burst of prednisone at 2mg/kg/
day improved clinical symptoms. The child was
admitted 2 months later to the ICU with right heart
failure, and an echocardiogram showed suprasystemic
right heart pressures (tricuspid regurgitation jet
75mmHg) with decreased right ventricular systolic
function. He was initiated on nasal cannula-inhaled
nitric oxide, milrinone, and furosemide on admission.
The next day, bosentan and intravenous methyl-
prednisone at 4mg/kg/day were added. Within
72 hours of steroid initiation, milrinone and inhaled
nitric oxide were weaned off, and an echocardiogram
showed right ventricular pressures that were half
systemic (tricuspid regurgitation jet 40mmHg). The
child was discharged home on sildenaﬁl, furosemide,
bosentan, and a 2.5-month prednisolone taper. Now at
6 years of age, he is maintained on sildenaﬁl and
ambrisentan with no further admissions.
Discussion
The role of inﬂammatory cell lines and cytokines in the
pathogenesis of pulmonary arterial hypertension as
well as steroid-induced improvement in clinical and
laboratory indicators in animal models has been well
described in the literature.2 Given this compelling
evidence and the low side-effect proﬁle of steroids, why
are there no studies examining the possible beneﬁts of
glucocorticoids in treating people with pulmonary
hypertension? Outside of patients with pulmonary
hypertension secondary to sarcoidosis, there is only a
single case report of an adult female with idiopathic
pulmonary hypertension who showed marked improve-
ment in her pulmonary hypertension after treatment
with prednisolone for idiopathic thrombocytopaenic
purpura.6 We have found no studies suggesting its
usefulness in children.
Our two cases demonstrate what we feel is a
relatively clear cause and effect regarding the beneﬁt of
glucocorticoids in treating children with pulmonary
hypertension. In addition to these two children, we have
treated a number of others cases that we feel improved
with steroid therapy. Simultaneous treatments make the
argument for the speciﬁc role of glucocorticoids more
difﬁcult; nonetheless, we felt that children who respond
best to steroids were usually less than 2 years of age, and
often with a diagnosis other than idiopathic pulmonary
hypertension. Interestingly, diseases with some degree of
alveolar hypoplasia seemed particularly responsive
including bronchopulmonary dysplasia, congenital
diaphragmatic hernia, giant omphalocele, and trisomy
21. Our current practice is to initiate a 5–7-day steroid
burst of either prednisone or methylprednisone at 2mg/
kg/day (up to 4mg/kg/day), a dose comparable with
treatment regimens for children with reactive airway
disease. If there is no clinical or echocardiographic
improvement in pulmonary hypertension, we stop the
steroids. If there is improvement, we begin a taper of
0.5mg/kg/week with the total treatment period lasting
about a month. Near the end of the treatment period,
we re-assess for rebound pulmonary hypertension.
Oftentimes, other pulmonary hypertensive medications
such as sildenaﬁl were utilised concomitantly. Occa-
sionally, we have found it helpful to extend treatment
courses, utilising every other day dosing or intermittent
bursts in hopes of avoiding long-term side-effects. We
have not seen any adverse complications secondary to use
of steroids in these children.
Inﬂammation plays an unequivocal role in the
pathogenesis of pulmonary hypertension based on
laboratory and animal data; furthermore, our clinical
observations suggest that modulating inﬂammation
using glucocorticoids may beneﬁt children with
pulmonary hypertension. Thus, given the unequivocal
role inﬂammation plays in pulmonary hypertension
based on laboratory and animal data as well as our
observations, we advocate for controlled clinical
trials to assess the potential effectiveness of steroids
in treating pulmonary hypertension in children.
A similar view has been suggested for treatment of
adults with pulmonary hypertension.7 Proof of their
utility could have signiﬁcant implications for child
health, given the ready availability of glucocorticoids,
their immense affordability compared with other
pulmonary hypertension medications, and their rela-
tively low side-effect proﬁle.
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